ACME LaboratoriesDHA:ACMELAB +0.36%90 Days Inventory is 180.65 as of Mar. 2026, which is 21% above its 10-year median of 148.83. GuruFocus rates DHA:ACMELAB with a GF Score™ of 90/100 and a GF Value™ of BDT125.51 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 919 Drug Manufacturers companies, ACME Laboratories ranks worse than 77.04% on this metric.
The historical rank and industry rank for ACME Laboratories's Days Inventory or its related term are showing as below:
DHA:ACMELAB'
s Days Inventory Range Over the Past 10 Years
Min: 145.7 Med: 148.83 Max: 254.71
Current: 254.71
During the past 9 years, ACME Laboratories's highest Days Inventory was 254.71. The lowest was 145.70. And the median was 148.83.
DHA:ACMELAB's Days Inventory is ranked worse than 77.04% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs DHA:ACMELAB: 254.71
ACME Laboratories's Days Inventory
declined
from Dec. 2024 (218.09) to Mar. 2026 (180.65).
Inventory Turnover measures how fast the company turns over its inventory within a year.
ACME Laboratories's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ACME Laboratories's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.17.
ACME Laboratories (DHA:ACMELAB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ACME Laboratories's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ACME Laboratories's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ACME Laboratories Days Inventory Related Terms
ACME Laboratories Days Inventory Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Days Inventory distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Days Inventory of 180.65 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ACME Laboratories and its competitors. This is 21% above median its historical median of 148.83. Over the past decade, ACME Laboratories' Days Inventory has ranged from 145.70 to 254.71. According to the industry distribution chart, ACME Laboratories ranks #708 out of 919 companies in the Drug Manufacturers industry, placing it in the top 77%.
Is ACME Laboratories' Days Inventory too high?
ACME Laboratories' current Days Inventory of 180.65 is 21% above median its 10-year median of 148.83. Over the past 10 years, this metric has ranged from a low of 145.70 to a high of 254.71. The Drug Manufacturers industry median Days Inventory is 164.38. ACME Laboratories' value of 180.65 is 9.9% above this industry median. Based on the distribution chart, ACME Laboratories ranks #708 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ACME Laboratories has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #708 out of 919 companies for Days Inventory. This places ACME Laboratories in the lower half of its industry. The industry median Days Inventory is 164.38. ACME Laboratories' value of 180.65 is 9.9% above this benchmark. Historically, ACME Laboratories' own Days Inventory has ranged from 145.70 to 254.71 over the past decade. While the company's 10-year median is 148.83 vs. the industry median of 164.38, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Days Inventory of 180.65 is 9.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Days Inventory is 180.65, which is 21% above median its own 10-year median of 148.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.51, compared to a current price of BDT84.50 — trading 32.7% below its estimated fair value. The current Days Inventory is 180.65, which is 21% above median its 10-year median of 148.83 and 9.9% above the Drug Manufacturers industry median of 164.38. ACME Laboratories' overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Days Inventory is 180.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT84.50 is trading 32.7% below its estimated GF Value™ of BDT125.51.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Days Inventory: 180.65 (21% above median its 10-year median of 148.83)
GF Value™: BDT125.51 vs. price of BDT84.50 (32.7% below fair value)
Industry Position: 9.9% above the Drug Manufacturers median (#708 of 919)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
90GF Score
Get the complete analysis for DHA:ACMELAB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
